首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2020年 9期“肝硬化临床终点事件的预测模型及应用” => 肝脏肿瘤 =>恩替卡韦单药与联合干..
恩替卡韦单药与联合干扰素抗病毒治疗对慢性乙型肝炎患者肝细胞癌发生风险的影响
Effect of entecavir antiviral therapy alone or combined with interferon on the risk of hepatocellular carcinoma in patients with chronic hepatitis B
文章发布日期:2020年08月22日  来源:  作者:孙静,朱琳,池欣,等  点击次数:650次  下载次数:51次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的 探究恩替卡韦(ETV)联合干扰素(IFN)治疗与ETV单药治疗对慢性乙型肝炎相关肝细胞癌(HCC)发生的影响。方法 回顾性选取2008年1月-2014年12月在北京地坛医院收治的409例慢性乙型肝炎患者,根据抗病毒治疗方式不同分为联合IFN组(n=169,IFN治疗≥6个月)及ETV单药组(n=240,ETV治疗≥12个月),随访截止至2019年6月,以观察对象发生HCC为终点事件。连续变量两组间比较采用Mann-Whitney U检验,分类变量两组间比较采用χ2检验。倾向评分匹配法(PSM)消除组间基线差异,Kaplan-Meier法及log-rank检验用于比较组间的HCC发生率,Cox比例风险回归模型分析影响HCC发生的危险因素。结果 研究中位随访时间为5.4(4.9~7.9)年。联合IFN组HCC累积发病率与ETV单药组相比,匹配前后差异均无统计学意义(PSM前:1.2% vs 2.8%, χ2=1.423,P=0.233;PSM后:1.7% vs 4.1%, χ2=1.676,P=0.195);亚组分析表明,在非高风险患癌人群中两组HCC累积发病率也无明显差异(1.3% vs 1.5%, χ2=0.335,P=0.563)。Cox比例风险回归模型显示年龄是HCC发生的独立危险因素(危险比=1.107,95%置信区间:1.005~1.219,P=0.038)。结论 对于非高患癌风险的慢性乙型肝炎患者,应用ETV联合IFN治疗至少6个月与ETV单药治疗相比,HCC发生风险未明显降低。
【Abstract】:Objective To investigate the effect of entecavir (ETV) alone or combined with interferon (IFN) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Methods A retrospective analysis was performed for 409 patients with CHB who were admitted to Beijing Ditan Hospital from January 2008 to December 2014, and according to their antiviral therapy, they were divided into ETV+IFN group with 169 patients (IFN treatment for ≥6 months) and ETV group with 240 patients (ETV treatment for ≥12 months). The patients were followed up to June 2019, and the development of HCC was the outcome event. The Mann-Whitney U test was used for comparison of continuous variables between two groups, and the chi-square test was used for comparison of categorical variables between two groups. The propensity score matching (PSM) method was used to eliminate baseline differences between groups, the Kaplan-Meier method and the log-rank test were used to compare the incidence rate of HCC between groups, and the Cox proportional-hazards regression model analysis was used to investigate the risk factors for the development of HCC. Results The median follow-up time in this study was 5.4 years (IQR: 4.9-7.9). There was no significant difference in the cumulative incidence rate of HCC between the two groups before and after PSM (before PSM: 1.2% vs 2.8%, χ2=1.423, P=0.233; after PSM: 1.7% vs 4.1%, χ2=1.676, P=0.195), and the subgroup analysis also showed no significant difference in the cumulative incidence rate of HCC between the two groups in the non-high risk population (1.3% vs 1.5%, χ2=0.335, P=0.563). The Cox proportional-hazards regression model showed that age was an independent risk factor for HCC (hazard ratio=1.107, 95% confidence interval: 1.005-1.219, P=0.038). Conclusion For CHB patients without a high risk of cancer, compared with ETV monotherapy, ETV combined with IFN for at least 6 months does not significantly reduce the risk of HCC.
【关键字】:乙型肝炎,慢性; 癌, 肝细胞; 干扰素类; 恩替卡韦; 对比研究
【Key words】:hepatitis B,chronic; carcinoma,hepatocellular; interferons; entecavir; comparative study
【引证本文】:SUN J, ZHU L, CHI X, et al. Effect of entecavir antiviral therapy alone or combined with interferon on the risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. J Clin Hepatol, 2020, 36(9): 1975-1979. (in Chinese)
孙静, 朱琳, 池欣, 等. 恩替卡韦单药与联合干扰素抗病毒治疗对慢性乙型肝炎患者肝细胞癌发生风险的影响[J]. 临床肝胆病杂志, 2020, 36(9): 1975-1979.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号